PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  05/27 04:03:15 pm EDT
53.91 USD   -0.15%
05/27PFIZER INC : Berenberg sticks Neutral
MD
05/27ViiV Healthcare commits to grant voluntary licence for patents relating to cabotegravir long-acting for PrEP to Medicines Patent Pool
AQ
05/274D pharma Plans Phase 2 Trial for Metastatic Urothelial Carcinoma Maintenance Therapy
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Canada study of Merck's COVID-19 oral treatment is moving more slowly - health minister

01/17/2022 | 02:13pm EDT

OTTAWA, Jan 17 (Reuters) - Canada's study into whether to approve Merck & Co Inc's COVID-19 oral antiviral treatment "is moving more slowly", federal Health Minister Jean-Yves Duclos said on Monday.

"There are some specific issues for this medication," Duclos told reporters after Ottawa approved an oral antiviral treatment by Pfizer Inc, but did not give details. In its pivotal clinical trial, Merck's pill had less impressive results than the one produced by Pfizer. (Reporting by David Ljunggren)


© Reuters 2022
All news about PFIZER, INC.
05/27PFIZER INC : Berenberg sticks Neutral
MD
05/27ViiV Healthcare commits to grant voluntary licence for patents relating to cabote..
AQ
05/274D pharma Plans Phase 2 Trial for Metastatic Urothelial Carcinoma Maintenance Therapy
MT
05/26ZOOM VIDEO COMMUNICATIONS, INC. : An attempt to reconnect
05/26Pfizer Receives US FDA Fast Track Designation for Ervogastat/Clesacostat Combination to..
MT
05/26Malawi Among 5 First Five African Countries to Benefit From Pfizer Health Accord
AQ
05/26Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for th..
BU
05/26Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for th..
CI
05/26Pfizer Launches 'An Accord for a Healthier World' to Improve Health Equity for 1.2 Bill..
AQ
05/26Supreme Court says watchdogs should pay fees
AQ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 104 B - -
Net income 2022 35 662 M - -
Net cash 2022 15 298 M - -
P/E ratio 2022 8,99x
Yield 2022 3,01%
Capitalization 302 B 302 B -
EV / Sales 2022 2,76x
EV / Sales 2023 3,56x
Nbr of Employees 79 000
Free-Float 58,2%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 53,91 $
Average target price 57,50 $
Spread / Average Target 6,67%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-8.70%302 483
JOHNSON & JOHNSON5.86%476 521
ELI LILLY AND COMPANY17.11%291 184
ROCHE HOLDING AG-13.00%281 098
ABBVIE INC.10.78%265 067
NOVO NORDISK A/S0.49%241 552